Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. Tomorrow, March 6, 2013, 43 U.S. common stocks are scheduled to go ex-dividend. The dividend yields on these stocks range from 0.1% to 9.7%. All of these stocks can be found on our stocks going ex-dividend section of our dividend calendar. Highlighted Stocks Going Ex-Dividend Tomorrow:
Owners of Mindray Medical International (NYSE: MR) shares as of market close today will be eligible for a dividend of 46 cents per share. At a price of $38.40 as of 9:35 a.m. ET, the dividend yield is 1.2%. The average volume for Mindray Medical International has been 731,700 shares per day over the past 30 days. Mindray Medical International has a market cap of $4.4 billion and is part of the health services industry. Shares are up 17.2% year to date as of the close of trading on Monday. EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys dividend stocks that have the potential for a 3% to 4% yield and 10% growth. Get his best picks for less than $50/year. Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. The company has a P/E ratio of 20.88. Currently there are 7 analysts that rate Mindray Medical International a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Mindray Medical International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Mindray Medical International Ratings Report now.